Kronos Bio
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 2017-01-01
- Employees
- 62
- Market Cap
- $60.1M
- Website
- http://www.kronosbio.com
- Introduction
Kronos Bio, Inc. is a clinical development biopharmaceutical company. It engages in the business of developing therapeutics that target dysregulated transcription that causes cancer and other serious diseases. The company was founded by Arie S. Belldegrun, Joshua A. Kazam, David M. Tanen, and Christopher Wilfong on June 2, 2017 and is headquartered in San Mateo, CA.
A Study to Evaluate Lanraplenib (LANRA) in Combination With Gilteritinib in Participants With FLT3-mutated Relapsed or Refractory Acute Myeloid Leukemia (AML)
- Conditions
- Acute Myeloid LeukemiaRelapsed Acute Myeloid LeukemiaRefractory Acute Myeloid Leukemia
- Interventions
- First Posted Date
- 2021-08-31
- Last Posted Date
- 2024-08-07
- Lead Sponsor
- Kronos Bio
- Target Recruit Count
- 24
- Registration Number
- NCT05028751
- Locations
- 🇪🇸
Institut Català d'Oncologia - Hospital Duran i Reynals (ICO L'Hospitalet), Barcelona, Spain
🇺🇸The Blood and Marrow Transplant Group of Georgia, Atlanta, Georgia, United States
🇺🇸Memorial Sloan Kettering Cancer Center, New York, New York, United States
Entospletinib Plus Intensive Induction/Consolidation Chemotherapy in Newly Diagnosed NPM1-mutated AML
- Conditions
- Nucleophosmin 1-mutated Acute Myeloid Leukemia
- Interventions
- First Posted Date
- 2021-08-25
- Last Posted Date
- 2024-01-10
- Lead Sponsor
- Kronos Bio
- Target Recruit Count
- 15
- Registration Number
- NCT05020665
- Locations
- 🇺🇸
Mount Sinai Health System, New York, New York, United States
🇫🇷Hôpital Côte De Nacre, Caen, Calvados, France
🇺🇸Hollings Cancer Center, Charleston, South Carolina, United States
A Study of KB-0742 in Participants With Relapsed or Refractory Solid Tumors Including Platinum Resistant High Grade Serous Ovarian Cancer (HGSOC)
- Conditions
- Relapsed Solid TumorsRefractory Solid TumorsNon-Hodgkin LymphomaHGSOCPlatinum Resistant High Grade Serous Ovarian Cancer
- Interventions
- First Posted Date
- 2021-01-22
- Last Posted Date
- 2025-02-17
- Lead Sponsor
- Kronos Bio
- Target Recruit Count
- 135
- Registration Number
- NCT04718675
- Locations
- 🇺🇸
O'Neal Comprehensive Cancer Center at the University of Alabama, Birmingham, Alabama, United States
🇺🇸City of Hope, Duarte, California, United States
🇺🇸MemorialCare - Orange Coast Medical Center, Fountain Valley, California, United States